20,007 Shares in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Bought by Rhumbline Advisers

Rhumbline Advisers acquired a new stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,007 shares of the company’s stock, valued at approximately $150,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bain Capital Life Sciences Investors LLC acquired a new position in Kyverna Therapeutics during the 1st quarter worth approximately $78,590,000. Jennison Associates LLC bought a new position in shares of Kyverna Therapeutics in the 1st quarter worth $34,743,000. Price T Rowe Associates Inc. MD acquired a new stake in Kyverna Therapeutics in the 1st quarter valued at $23,093,000. Janus Henderson Group PLC bought a new stake in Kyverna Therapeutics during the 1st quarter valued at $15,041,000. Finally, Avoro Capital Advisors LLC acquired a new position in Kyverna Therapeutics during the first quarter worth $11,799,000. Institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Stock Down 0.4 %

Shares of KYTX opened at $5.23 on Monday. The stock has a 50 day moving average of $7.41 and a 200 day moving average of $12.80. Kyverna Therapeutics, Inc. has a 12 month low of $5.15 and a 12 month high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its earnings results on Monday, August 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.03. Research analysts predict that Kyverna Therapeutics, Inc. will post -3.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

KYTX has been the subject of several recent research reports. JPMorgan Chase & Co. decreased their target price on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating for the company in a research report on Wednesday, July 31st. HC Wainwright restated a “neutral” rating and issued a $7.00 target price on shares of Kyverna Therapeutics in a report on Thursday, September 19th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $34.40.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.